Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience
Kevin Yijun Fan, Michelle Ku, Beatriz Jimenez Munarriz, Tracy Stockley, Andrew Rabinovitch, Geoffrey Liu, Penelope Bradbury, Natasha B. Leighl · 2026
Read Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience by Kevin Yijun Fan, Michelle Ku, Beatriz Jimenez Munarriz, Tracy Stockley, Andrew Rabinovitch, Geoffrey Liu, Penelope Bradbury, Natasha B. Leighl (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13579456.txt.
Description
Kevin Yijun Fan and colleagues report a three drug salvage plan for lung cancer that outgrew its first targeted drug, in a 2026 single center account from Toronto. The cancers carried a fault in a growth gene, and a drug aimed at that fault worked until a second fault, in the BRAF gene, opened an escape route. Five patients were treated with two added drugs that block the escape path at two points, alongside the first drug.
One patient shrank her tumor and held the gain for close to three years, with brain spread controlled as well. The other four saw their disease push on within months. Two patients paused or stopped treatment over gut side effects, and no fever appeared, a known risk with this drug class. The authors call for larger studies in hand picked patients.
Catalog record
| CREATOR | Kevin Yijun Fan, Michelle Ku, Beatriz Jimenez Munarriz, Tracy Stockley, Andrew Rabinovitch, Geoffrey Liu, Penelope Bradbury, Natasha B. Leighl |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |